Table 1 Distribution of demographic and clinical characteristics according to different lipid-lowering strategies in AMI patients
Statin | Statin+ Ezetimibe | Statin+ Evolocumab | Statin+ Ezetimibe+ Evolocumab | ||
|---|---|---|---|---|---|
Age (years) | 62.90 ± 11.91 | 58.73 ± 12.16 | 57.72 ± 11.07 | 54.38 ± 11.77 | |
Female Sex(%) | 20.3 | 21.0 | 15.7 | 18.8 | |
SBP (mmHg) | 123.41 ± 22.24 | 125.20 ± 22.79 | 127.54 ± 22.20 | 122.72 ± 23.04 | |
DBP (mmHg) | 77.17 ± 14.53 | 79.01 ± 15.02 | 82.36 ± 14.49 | 78.98 ± 15.32 | |
EF(%) | 51.11 ± 10.27 | 52.81 ± 10.39 | 51.11 ± 10.27 | 51.27 ± 9.72 | |
Pro-BNP (pg/mL) | 2071.69 | 1334.93 | 2071.69 | 1135.26 | |
HbA1c(%) | 6.33 ± 1.45 | 6.29 ± 1.44 | 6.33 ± 1.45 | 6.75 ± 2.00 | |
Cre (umol/L) | 77.94 | 70.48 | 69.36 | 62.97 | |
UA (umol/L) | 333.91 | 340.59 | 330.43 | 330.08 | |
TG (mmol/L) | 1.48 ± 0.99 | 1.94 ± 0.66 | 1.57 ± 0.74 | 1.92 ± 1.02 | |
HDL (mmol/L) | 0.93 ± 0.22 | 0.98 ± 0.24 | 1.00 ± 0.21 | 1.00 ± 0.23 | |
TCDL (mmol/L) | 3.93 ± 0.99 | 4.76 ± 1.25 | 4.96 ± 1.19 | 5.69 ± 1.50 | |
ApoA(g/L) | 1.05 ± 0.19 | 1.09 ± 0.19 | 1.09 ± 0.17 | 1.09 ± 0.20 | |
ApoB(g/L) | 0.77 ± 0.20 | 0.95 ± 0.24 | 1.00 ± 0.23 | 1.16 ± 0.29 | |
ApoE (mg/L) | 35.64 ± 14.04 | 41.59 ± 18.67 | 41.96 ± 12.92 | 46.68 ± 19.88 | |
Lp(a) (mg/L) | 261.68 | 302.22 | 330.56 | 368.69 | |
Death (%) | 1.9 | 0.7 | 0.8 | 0.0 | |
Readmission (%) | 10.4 | 14.7 | 4.0 | 5.3 | |
LDL (mmol/L) | Admission | 2.25 ± 0.74 | 2.95 ± 1.03 | 3.24 ± 0.98 | 3.90 ± 1.45 |
Under Target | 11.8 | 4.0 | 3.2 | 1.3 | |
Follow-up(1 m) | 1.60 ± 0.51 | 1.87 ± 0.75 | 0.93 ± 0.63 | 1.41 ± 1.02 | |
Under Target | 37.0 | 28.8 | 79.5 | 55.3 | |
Follow-up(3 m) | 1.60 ± 0.54 | 1.90 ± 0.82 | 1.13 ± 0.67 | 1.40 ± 0.50 | |
Under Target | 40.6 | 29.3 | 80.0 | 43.8 | |